newsfilter
← Latest News
GlobeNewswire·

GH Research Announces Novel Therapies Symposium Presentation and Posters at the 2025 ECNP Congress

  • GH Research PLC announced the acceptance of one Novel Therapies Symposium presentation & two posters on GH001 at the 38th Annual ECNP Congress in Amsterdam from October 11–14.
  • Professor Wiesław J. Cubała will present long-term safety & efficacy data from the open-label extension of the Phase 2b GH001-TRD-201 trial on October 13 at 3:00pm CET.
  • Two additional posters will present safety & tolerability data & psychoactive effects of GH001 from the same trial, presented by Fabian Devlin on October 13 at 12:35pm CET & Bernhard T. Baune on October 14 at 12:35pm CET.
  • Principal investigator Professor Bernhard Baune stated that the 6-month open-label extension confirmed GH001's favorable safety profile with no treatment-related serious adverse events or suicidal intent.
  • GH Research is organizing an Industry Satellite Symposium titled "Time Matters" on rapid-acting antidepressants in TRD on October 12 from 8:40am to 10:00am CET.
  • GH001 is a mebufotenin therapy administered via inhalation that met its primary endpoint in Phase 2b trials with a MADRS reduction of -15.5 points versus placebo on Day 8.